BioMimetic, headquartered in Franklin, Tenn., specializes in the development and commercialization of products designed to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic and sports medicine applications. The company’s Augment bone graft, a replacement for autologous bone graft in foot and ankle fusions, is under late stage FDA review.
Wright will pay an upfront purchase price of $190 million in cash and stock plus contingent payments of up to $190 million for BioMimetic.
“We believe this transaction will significantly accelerate the continued transformation of our business as well as our strategy of building a world-class biologics platform and growing our foot and ankle business at well above market growth rates,” said Robert Palmisano, president and CEO of Wright, in the release. “BioMimetic’s products complement our existing biologics product portfolio, and, if approved by the FDA as we expect, Augment bone graft will provide us with a unique solution for the U.S. hindfoot and ankle fusion market that leverages the distribution capabilities of Wright’s dedicated foot and ankle sales organization and our physician training capabilities.”
The transaction is expected to close in the first quarter of 2013.
Wright Medical Group is headquartered in Arlington, Tenn.
Related Articles on Company Acquisitions:
Allergan to Acquire SkinMedica
Alphatec Spine Completes Acquisition of Phygen
GE Healthcare Acquires U-Systems
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.